APTX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Dec 2023 @ 15:59):

Stats
Today's Volume	231 126
Average Volume	132 918
Market Cap	6.50M
EPS	$0 ( 2024-04-04 )
Next earnings date	( $0 ) 2024-05-16
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0980
ATR14	$0.00400 (4.17%)

Insider Trading

Date	Person	Action	Amount	type
2023-01-03	Khanna Ashish	Buy	375 000	Stock Option (Right to Buy)
2023-01-03	Riedel Norbert G	Buy	420 000	Stock Option (Right to Buy)
2023-01-03	Kidd Andrew	Buy	700 000	Stock Option (Right to Buy)
2022-05-26	Koppel Adam	Buy	40 000	Stock Option (Right to Buy)
2022-05-26	Koppel Adam	Buy	40 000	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 97 transactions
Buy: 16 590 862 \| Sell: 1 518 818

Volume Correlation

Long: 0.42 (neutral)

Short: 0.45 (neutral)

Signal:(66.425) Neutral

Aptinyx Inc Correlation

10 Most Positive Correlations
GNUS	0.981
UEIC	0.973
GMBL	0.966
QNRX	0.946
FAMI	0.945
BAND	0.945
JAGX	0.943
INFI	0.942
PIXY	0.94
GROM	0.938

10 Most Negative Correlations
AGFS	-0.94
APEN	-0.935
LMRK	-0.889
SGEN	-0.885
KNBE	-0.884
TIG	-0.883
MYRG	-0.876
RDUS	-0.875
QADA	-0.871
IMRA	-0.862

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aptinyx Inc Correlation - Currency/Commodity

0.20
( neutral )

0.30
( neutral )

0.00
( neutral )

-0.12
( neutral )

Aptinyx Inc Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.950

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.320

Q4	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0.380

Q3	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.220

Financial Reports:

No articles found.

Aptinyx Inc

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.